Portal de Periódicos da CAPES

SEROTONIN ANTAGONISTS

1984; Wiley; Volume: 14; Issue: 6 Linguagem: Inglês

10.1111/j.1445-5994.1984.tb03802.x

0004-8291

Michael Anthony,

Glycogen Storage Diseases and Myoclonus

Australian and New Zealand Journal of MedicineVolume 14, Issue 6 p. 888-895 SEROTONIN ANTAGONISTS M. ANTHONY, Corresponding Author M. ANTHONY The Department of Neurology, Prince Henry Hospital and the School of Medicne, University of New South Wales, Sydney, NSWSchool of Medicine, University of New South Wales, P.O. Box 1, Kensington, New South Wales, 2033.Search for more papers by this author M. ANTHONY, Corresponding Author M. ANTHONY The Department of Neurology, Prince Henry Hospital and the School of Medicne, University of New South Wales, Sydney, NSWSchool of Medicine, University of New South Wales, P.O. Box 1, Kensington, New South Wales, 2033.Search for more papers by this author First published: December 1984 https://doi.org/10.1111/j.1445-5994.1984.tb03802.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Erspamer V. Pharmacology of indolealkylamines. Pharmacol Rev 1954; 6: 425– 87. 2 Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin): chemical inactivation. J Biol Chem 1948; 176: 1237– 41. 3 Lembeck F. 5-Hydroxytryptamine in carinord tumour. Nature 1953; 172: 910– 1. 4 Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In: Goodman and Gillman (eds). The pharmacological basis of therapeutics. 6th edition. New York : Macmillan, 1980: 609– 646. 5 Undenfriend S., Bodanski DE, Weissbach H. Fluorescence characteristics of 5-hydroxytryptamine (serotonin). Science 1955; 122: 972– 3. 6 Messing RB, Lytle LD. Serotonin containing neurones: their possible role in pain and analgesia. Pain 1977; 4: 1– 21. 7 Fozard JR. The animal pharmacology of drugs used in the treatment of migraine. J Pharm Pharmacol 1975; 27: 297– 321. 8 Awouters F., Leysen JE, De Clerck F., Van Neuten JM. General pharmacological profile of ketanserin (R 41.468), a selective 5HT, receptor antagonist. In: F. De Clerck, PM Vanhoute (eds). 5-hydroxytryptamine in peripheral reactions. New York : Raven Press, 1982: 193– 7. 9 Schachter M., Grahame-Smith DG. 5-Hydroxytryptarnine and the platelet: specific binding and active uptake. In: F. De Clerck PM Vanhoute (eds). 5-Hydroxytryptamine in peripheral reactions. New York : Raven Press, 1982: 49– 59. 10 Garattini S., Samanin R. Drugs affecting serotonin: a survey. In: WB Eisman (ed.). Physiological regulation and pharmacological action. Vol 2, Serotonin in health and disease. New York : Spectrum Publications Inc, 1978: 247– 93. 11 Aghajanian GK, Wang RY. Physiology and pharmacology of central serotoninergic neurons. In: MA Lipton, A. DiMascio, KF Killan (eds). Psychopharmacology: a generation of progress. New York : Raven Press, 1978: 171– 83. 12 Berde B., Sturmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: B. Berde, HO Schild (eds). Ergot alkaloids and related compounds. Hanbuch der Experimentellen pharmacologie. Berlin : Springer Verlag, 1978; 49: 1– 28. 13 Berde B. Recent progress in the elucidation of the mechanism of action of ergot compounds used in migraine. Med J Aust 1972; 2: 15– 6. 14 Spira PJ, Mylecharane EJ, Lance JW. The effect of humoral agents and antimigraine drugs on the cranial circulation of the monkey. Res Clin Stud Headache 1976; 4: 37– 75. 15 Edmeads J., Hachinski VC, Norris JW. Ergotamine and the cerebral circulation. Hemicrania 1976; 7: 6– 10. 16 Tfelt-Hansen P., Ibraheem JJ, Paallow L. Clinical pharmacology of ergoiamine studies with a HPLC method. In: FC Rose (ed.) Advances in migraine research and therapy. New York ; Raven Press, 1982: 173– 9. 17 Anthony M. Drugs in migraine. Curr Therapeutics 1983; 24: 89– 113. 18 Curran DA, Hinterberger H., Lance JW. Methysergide. Res Clin Stud Headache 1967; 1: 74– 122. 19 Saxena PR. Selective vasoconstriction in carotid vascular bed by methysergide: possible relevance to its antimigraine effects. Eur J Pharmacol 1974; 27: 99– 105. 20 Saxena PR. The effect of antimigraine drugs on the vascular responses to 5-hydroxytryptamine and related biogenic substances on the carotid artery bed of dogs. Headache 1972; 12: 44– 54. 21 Carroll PR, Ebeling PW, Glover WE. The response of the human temporal and rabbit ear artery to 5-hydroxytryptamine and some of its anagnnists. Aust J Exp Eiol Med Sci 1974; 52: 813– 23. 22 Dalesio DJ. On migraine headache: serotonin and serotonin antagonism. J Am Med Assoc 1962; 181: 318– 21. 23 Halmagyi DJF, Colebatch HJH. Serotonin-like cardiorespiratory effects of a serotonin antagonist. J Pharmacol (Baltimore) 1961; 134: 47– 52. 24 Fanchamps A., Doepfner W., Weidmann H., Cerletti A. Pharmacolonische charakterisierung von Deseril einem Serotonin-antagonisten. Schweiz Med Wscher 1960; 90: 1040– 6. 25 Poulson E., Robson JM. Prevention by antagonists of the action of 5-hydroxytryptamine in pregnancy. Br J Pharmacol 1963; 21: 150– 4. 26 Lance JW, Anthony M., Somerville BW. Comparative trial of serotonin antagonists in management of migraine. Br Med J 1970; 2: 327– 30. 27 Curran DA, Lance JW. Clinical trial of methysergide and other preparations in the management of migraine. J Neurol Nenrosurg Psychiat 1964; 27: 463– 9. 28 Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967; 254: 1– 12. 29 Speight TM, Avery GS. Pizotifen (BC105) a review of its pharmacological properties and its therapeutic efficacy in vascular headache. Drugs 1972; 3: 159– 203. 30 Fraipont-Guyot C., Luyckz A., Lefebre P. Study of the effects of serotonin antagonist (BC-105 Sandoz) on carbohydrate metabolism. Rev Med Liege 1970; 25: 414– 21. 31 Cerdan A., Acosta M., John T. Long term administration of pizotifen to migraine patients; effects of oral glucose tolerance tests on insulin levels. Headache 1976; 15: 125– 8. 32 Feldman JM, Lebowitz HE. Control of insulin and growth hormone secretion by serotonin and dopamine. IVth International Congress of Endocrinology, Washington, June 1972, Excerpta Medica: 1972: 35. 33 Smythe GA, Lazarus L. Suppression of growth hormone secretion by melatonin and cyproheptadine. J Clin Invest 1974; 54: 116– 21. 34 Bivens CH, Lebowitz HE, Feldman JM. Inhibition of hypoglycaemia-induced growth hormone secretion by the serotonin antagonists cyproheptadine and methysergide. N Engl J Med 1973; 289: 236– 9. 35 Herrmann WM, Horowski R., Dannehl K., Krarner U., Lurati K. Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide. Headache 1977; 17: 54– 60. 36 Somerville BW, Herrman MW. Migraine prophylaxis with lisuride hydrogen maleate—a double blind study of lisuride versus placebo. Headache 1978; 18: 75– 9. 37 Marshall KJ. The pharmacology of mianserin—an update. Br J Clin Pharmacol 1983; 15: 263S– 8S. 38 Clink HM. Mianserin and blood dyserasias. Br J Clin Pharmacol 1983; 15: 2915– 38. 39 Di Perri T., Laghi Pasini F., Vittoria A., Ceccatelli L. Hypotheses on the release of biologically active humoral mediators induced by Ketanscrin (R41468). In: F. De Clerck, PM Vanhoute (eds). 5-Hydroxytryptamine in peripheral reactions. New York : Raven Press, 1982: 213– 7. 40 De Cree J., Leempcels J., DeCock W., Glukens H., Verhaegen H. The antihypertensive effects of a pure and selective serotoninreceptor blocking agent (R41468) in elderly patients. Angiology 1981; 32: 137– 44. 41 Garattini S., Valzelli L. Serotonin. Amsterdam : Elsevier, 1965. Citing Literature Volume14, Issue6December 1984Pages 888-895 ReferencesRelatedInformation